hotspot -WSS

hotspot

author：entertainment 2025-08-23 18:38:08 - browse：149

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： 'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

entertainment

WSS

MoonLake credibility takes another hit with mid

Delta passengers in Vegas fall sick while waiting on flight in triple

In rare move, senator releases unverified FBI source report alleging Biden bribe

Removing probiotics from the NICU could threaten preemies' health

When a patient nears the end, a feared therapy can comfort

Caribou posts encouraging results on off

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

What does generative AI mean for health care? We asked experts

Just how powerful is the placebo effect?

Moonlake's readout produced a cash windfall. Risks remain

Ambulance rides for just $100? Advisers want major billing fixes

How to save PrEP access — and even expand it

Will General Catalyst be the first of many hospital takeovers?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Telehealth startups are trying to fill the menopause care vacuum

Affirmative action in medical school literally saved lives

HPV cancer vaccine study demonstrates efficacy

focus

Removing probiotics from the NICU could threaten preemies' health

Scientists grapple with ethics of stem cell research

Caribou posts encouraging results on off

Study: New antibiotic targets gonorrhea as well as last existing drug

The stock market has soared this year, but will it last? Experts weigh in

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

hotspot

entertainment

leisure time

leisure time